The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada

This publication has 20 references indexed in Scilit:

• Merck's Recall of Rofecoxib — A Strategic Perspective
  New England Journal of Medicine, 2004
• Drug Spending in Canada
  Medical Care, 2004
• Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study
  The Lancet, 2004
• Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.
  Archives of internal medicine (1960), 2003
• Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study
  The Lancet, 2002
• Risk of Cardiovascular Events Associated With Selective COX-2 Inhibitors
  JAMA, 2001
• The Coxibs, Selective Inhibitors of Cyclooxygenase-2
  New England Journal of Medicine, 2001
• Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
  New England Journal of Medicine, 2000
• Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
  JAMA, 2000
• Comparison of dose standard units for drug utilisation studies
  European Journal of Clinical Pharmacology, 1996